FDA Developing Guidance On Exploratory INDs; Lilly Endorses Concept
Executive Summary
FDA is developing a guidance on "exploratory" investigational new drug applications that will simplify toxicology requirements for "pre-Phase I" human trials, Clinical Pharmacology Lab Director Jerry Collins, PhD, said during an FDA workshop Nov. 16